MDL-800 SIRT6 activator reduced age-associated osteoarthritis in old male mice
In an abstract, 18-month-old male mice given weekly MDL-800 injections for 6 months showed less severe age-associated osteoarthritis at 24 months than vehicle controls; human cell experiments examined SIRT6-related pathways and DNA damage. [1]
Automatic summary · not editorially reviewed
The key findings
Male mice aged 18 months received weekly intraperitoneal MDL-800 or vehicle for 6 months, and osteoarthritis severity was assessed at 24 months. [1]
Mice given long-term MDL-800 showed less cartilage damage, osteophyte formation, synovial hyperplasia, subchondral bone sclerosis and meniscal ossification than controls. [1]
MDL-800 reduced oxidative stress-induced p38 phosphorylation in chondrocytes and basal DNA damage in human and mouse synovial fibroblasts. [1]
The source at a glance
- Study type / format
- Animal study in mice with supporting human and mouse cell experiments (abstract)
- Population / context
- Male mice aged 18 months at injection start, assessed at 24 months; human chondrocytes and human and mouse synovial fibroblasts in cell experiments.
- Summary based on
- Study abstract
- Original publication
- September 22, 2026
MDL-800 versus vehicle in aging male mice
The stated aim was to test whether systemic administration of MDL-800, a small-molecule activator of SIRT6, reduces the severity of age-associated osteoarthritis in mice. Male mice aged 18 months received weekly intraperitoneal injections of MDL-800 or a vehicle control for 6 months. Osteoarthritis severity was then assessed at 24 months by histology, micro-CT and histomorphometry. The comparison was therefore MDL-800 versus vehicle in aging male mice, not a comparison with exercise or another drug.
Supporting source [1]
Less joint damage in MDL-800 mice at 24 months
Mice given long-term MDL-800 were reported to be protected from osteoarthritis pathology compared with controls. The abstract lists less cartilage damage, fewer osteophytes (bony outgrowths), less synovial hyperplasia, less subchondral bone sclerosis and less meniscal ossification. In human chondrocytes, RNA sequencing showed that MDL-800 was associated with lower enrichment of pathways for bone formation, angiogenesis and catabolic MAP kinase signaling, and higher enrichment of pathways for epigenetic regulation, telomere maintenance, mitochondrial function, redox balance and DNA repair. MDL-800 also reduced oxidative stress-induced phosphorylation of p38 in chondrocytes and basal DNA damage in human and mouse synovial fibroblasts.
Supporting source [1]
Abstract-only scope of the mouse and cell findings
The authors conclude that SIRT6 activation by MDL-800 protected old mice from age-associated osteoarthritis severity in vivo and regulated multiple hallmarks of aging. They propose that therapies activating SIRT6 may be a strategy to slow, stop or reverse age-associated osteoarthritis. These are proposals, not an established treatment. Only the abstract was reviewed; the full text was not reviewed. The abstract does not report sample sizes per group, effect sizes, statistical details or harms, and the human chondrocyte and fibroblast work examined cells, not human lifespan or disease outcomes.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. The abstract does not report group sizes, effect sizes, statistical details or harms. The human chondrocyte and fibroblast experiments examined cells, not human lifespan or disease outcomes. The proposed SIRT6-activating therapy is not an established treatment.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Perez MM, Ramteke P, Watson B, Haslam O, Choi E, Chubinskaya S, Peffers MJ, Davis WR, Shine J, Diekman BO, Loeser RF, Freeman TA, Risbud MV, Collins JA. · europepmc.org · September 22, 2026